Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Detection of influenza A(H1N1)pdm09 virus in a patient travelling from Shanghai to Italy in July 2018: an uncommon clinical presentation in a non-seasonal period.

Butera F, Schenone S, Grammatico F, Tisa V, Barisione G, Guarona G, Bruzzone B, Murdaca G, Setti M, Orsi A.

J Prev Med Hyg. 2019 Mar 29;60(1):E1-E4. doi: 10.15167/2421-4248/jpmh2019.60.1.1214. eCollection 2019 Mar.

2.

Immunological profile of an infant treated with integrase inhibitor from the neonatal period.

Taramasso L, Dentone C, Tatarelli P, Bruzzone B, Marras F, De Maria A, Gotta C, Castagnola E, Filaci G, Viscoli C, Fenoglio D, Di Biagio A.

J Virus Erad. 2019 Jan 1;5(1):47-49. No abstract available.

3.

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.

Alteri C, Scutari R, Bertoli A, Armenia D, Gori C, Fabbri G, Mastroianni CM, Cerva C, Cristaudo A, Vicenti I, Bruzzone B, Zazzi M, Andreoni M, Antinori A, Svicher V, Ceccherini-Silberstein F, Perno CF, Santoro MM.

Virus Genes. 2019 Jun;55(3):290-297. doi: 10.1007/s11262-019-01649-z. Epub 2019 Feb 22.

PMID:
30796743
4.

Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.

Sterrantino G, Borghi V, Callegaro AP, Bruzzone B, Saladini F, Maggiolo F, Maffongelli G, Andreoni M, De Gennaro M, Gianotti N, Bagnarelli P, Vergori A, Antinori A, Zazzi M, Zaccarelli M; ARCA Study Group.

Int J Antimicrob Agents. 2019 Apr;53(4):515-519. doi: 10.1016/j.ijantimicag.2019.02.007. Epub 2019 Feb 12.

PMID:
30769200
5.

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.

Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A.

HIV Med. 2019 Feb;20(2):137-146. doi: 10.1111/hiv.12692. Epub 2018 Nov 21.

PMID:
30461149
6.

Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.

Zappulo E, Nicolini LA, Di Grazia C, Dominietto A, Lamparelli T, Gualandi F, Caligiuri P, Bruzzone B, Angelucci E, Viscoli C, Mikulska M.

Infection. 2019 Feb;47(1):59-65. doi: 10.1007/s15010-018-1214-5. Epub 2018 Sep 19.

PMID:
30232604
7.

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.

Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group .

Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun.

8.

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis).

J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21.

PMID:
29957545
9.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

10.

Correct Identification of Dual HCV Infections in HIV/HCV CoInfected Patients.

Bruzzone B, Canepa P, De Rosa G, Delucis S, D'Ambrosio B, Icardi G, Setti M.

AIDS Res Hum Retroviruses. 2018 Apr;34(4):325-326. doi: 10.1089/aid.2017.0133. Epub 2018 Jan 9. No abstract available.

PMID:
29314861
11.

Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?

Taramasso L, Riccardi N, Del Puente F, Bruzzone B, Ripamonti D, D'Ambrosio B, Viscoli C, Di Biagio A.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):168-170. doi: 10.1089/AID.2017.0112. Epub 2018 Jan 18.

PMID:
29166777
12.

CD8+CD28-CD127loCD39+ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?

Fenoglio D, Dentone C, Signori A, Di Biagio A, Parodi A, Kalli F, Nasi G, Curto M, Cenderello G, De Leo P, Bartolacci V, Orofino G, Nicolini LA, Taramasso L, Fiorillo E, Orrù V, Traverso P, Bruzzone B, Ivaldi F, Mantia E, Guerra M, Negrini S, Giacomini M, Bhagani S, Filaci G.

J Allergy Clin Immunol. 2018 Jun;141(6):2220-2233.e4. doi: 10.1016/j.jaci.2017.08.021. Epub 2017 Nov 2.

13.

Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy.

Bruzzone B, Magnani O, Sticchi L, Canepa P, Rappazzo E, Icardi G, Setti M.

J Antimicrob Chemother. 2017 Oct 1;72(10):2955-2958. doi: 10.1093/jac/dkx222. No abstract available.

PMID:
29091216
14.

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C).

J Hepatol. 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep 20. No abstract available.

PMID:
28939133
15.

Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study.

Grignolo S, Agnello R, Gerbaldo D, Gotta C, Alicino C, Del Puente F, Taramasso L, Bruzzone B, Gustavino C, Trasino S, DE Maria A, Icardi G, Viscoli C, DI Biagio A.

Epidemiol Infect. 2017 Jun;145(8):1658-1669. doi: 10.1017/S095026881700053X. Epub 2017 Mar 22.

PMID:
28325171
16.

Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.

Dentone C, Sterrantino G, Signori A, Cenderello G, Guerra M, De Leo P, Bartolacci V, Mantia E, Orofino G, Giacomini M, Bruzzone B, Francisci D, Di Biagio A; MARHIV Study Group.

Int J STD AIDS. 2017 Oct;28(11):1067-1073. doi: 10.1177/0956462416687828. Epub 2017 Jan 31.

PMID:
28142395
17.

Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy.

Trucchi C, Alicino C, Orsi A, Paganino C, Barberis I, Grammatico F, Canepa P, Rappazzo E, Bruzzone B, Sticchi L, Ansaldi F.

Hum Vaccin Immunother. 2017 Feb;13(2):456-463. doi: 10.1080/21645515.2017.1264779. Epub 2016 Dec 7.

18.

Xpert HIV-1 Viral Load Assay and VERSANT HIV-1 RNA 1.5 Assay: A Performance Comparison.

Bruzzone B, Caligiuri P, Nigro N, Arcuri C, Delucis S, Di Biagio A, Icardi G.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e86-e88. doi: 10.1097/QAI.0000000000001227. No abstract available.

PMID:
27828879
19.

Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.

Rossotti R, Borghi V, Callegaro AP, Micheli V, Bruzzone B, Colao G, Gismondo MR, Vicenti I, Penco G, Zazzi M, Rusconi S.

J Clin Virol. 2016 Oct;83:48-53. doi: 10.1016/j.jcv.2016.08.293. Epub 2016 Aug 23.

PMID:
27591555
20.

Vaginal HIV-1 shedding among HIV-1 infected women in the current era of combined antiretroviral therapy: A cross sectional study.

Grignolo S, Bruzzone B, Gabbi L, Gerbaldo D, Gallo F, Nigro N, Icardi G, Viscoli C, Di Biagio A.

Virulence. 2017 Jan 2;8(1):101-108. doi: 10.1080/21505594.2016.1216293. Epub 2016 Jul 26. No abstract available.

21.

HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes.

Tatarelli P, Taramasso L, Di Biagio A, Sticchi L, Nigro N, Barresi R, Viscoli C, Bruzzone B.

New Microbiol. 2016 Apr;39(2):150-2.

22.

First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.

Meini G, Dello Russo C, Allice T, Barresi R, D'Arrigo R, Falasca F, Lipsi MR, Paolucci S, Zanussi S, Antonetti R, Baldanti F, Basaglia G, Bruzzone B, Polilli E, Ghisetti V, Pucillo LP, Turriziani O, Pirazzoli A, Navarra P, Zazzi M.

J Clin Virol. 2016 May;78:1-3. doi: 10.1016/j.jcv.2016.02.020. Epub 2016 Feb 23.

PMID:
26946153
23.

Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.

Vicenti I, Falasca F, Sticchi L, Bruzzone B, Turriziani O, Zazzi M.

J Clin Virol. 2016 Mar;76:20-3. doi: 10.1016/j.jcv.2016.01.006. Epub 2016 Jan 12.

PMID:
26802683
24.

Overview of hepatitis B virus mutations and their implications in the management of infection.

Caligiuri P, Cerruti R, Icardi G, Bruzzone B.

World J Gastroenterol. 2016 Jan 7;22(1):145-54. doi: 10.3748/wjg.v22.i1.145. Review.

25.

Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.

Sticchi L, Di Biagio A, Sartini M, Rappazzo E, Nicolini LA, Cenderello G, Valle C, Azzola E, Grasso A, De Leo P, Boldrini A, Setti M, Prinapori R, Lorusso C, Bruzzone B, Icardi G; Ligurian HIV Network.

New Microbiol. 2015 Oct;38(4):499-509. Epub 2015 Oct 20.

26.

Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system.

Dentone C, Fenoglio D, Schenone E, Cenderello G, Prinapori R, Signori A, Parodi A, Kalli F, Battaglia F, Feasi M, Bruzzone B, Viscoli C, Filaci G, Di Biagio A.

HIV Clin Trials. 2015 Oct;16(5):190-6. doi: 10.1179/1945577115Y.0000000005. Epub 2015 Sep 13.

PMID:
26365593
27.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
28.

Role of HCV-RNA decay and IP-10 levels after 48 hours of standard HCV therapy as predictors of rapid virological response.

Prinapori R, Sticchi L, Alicino C, Del Puente F, Mazzarello G, Alessandrini A, Signori A, Icardi G, Bruzzone B, Viscoli C, Di Biagio A.

Clin Res Hepatol Gastroenterol. 2015 Dec;39(6):705-10. doi: 10.1016/j.clinre.2015.04.001. Epub 2015 Jun 10.

PMID:
26070571
29.

Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project).

Bruzzone B, Saladini F, Sticchi L, Mayinda Mboungou FA, Barresi R, Caligiuri P, Calzi A, Zazzi M, Icardi G, Viscoli C, Bisio F.

AIDS Res Hum Retroviruses. 2015 Aug;31(8):837-40. doi: 10.1089/AID.2015.0105. Epub 2015 Jun 2.

PMID:
25970260
30.

Pregnancy outcomes following exposure to efavirenz-based antiretroviral therapy in the Republic of Congo.

Bisio F, Nicco E, Calzi A, Giacobbe DR, Mesini A, Banguissa H, Vividila NE, Mahoungou P, Boumba JD, Mboungou FA, Bruzzone B, Ratto S, Icardi G, Viscoli C, Bruzzi P.

New Microbiol. 2015 Apr;38(2):185-92. Epub 2015 Apr 29.

31.

Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.

Sticchi L, Bruzzone B, Caligiuri P, Rappazzo E, Lo Casto M, De Hoffer L, Gustinetti G, Viscoli C, Di Biagio A.

Hum Vaccin Immunother. 2015;11(1):263-9. doi: 10.4161/hv.36162. Epub 2014 Nov 1.

32.

Darunavir-based dual therapy in HIV experienced patients.

Sterrantino G, Zaccarelli M, Di Biagio A, Rosi A, Bruzzone B, Cicconi P, Carli T, Biondi ML, Antinori A, Bartolozzi D, Penco G.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19782. doi: 10.7448/IAS.17.4.19782. eCollection 2014.

33.

Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL.

Dentone C, Fenoglio D, Signori A, Cenderello G, Parodi A, Bozzano F, Guerra M, De Leo P, Bartolacci V, Mantia E, Orofino G, Kalli F, Marras F, Fraccaro P, Giacomini M, Cassola G, Bruzzone B, Ferrea G, Viscoli C, Filaci G, De Maria A, Di Biagio A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19718. doi: 10.7448/IAS.17.4.19718. eCollection 2014.

34.

Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia.

Bruzzone B, Di Biagio A, Sticchi L, Barresi R, Saladini F, Icardi G, Setti M.

Antimicrob Agents Chemother. 2014 Dec;58(12):7620-1. doi: 10.1128/AAC.03771-14. No abstract available.

35.

Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports.

Taramasso L, Dentone C, Alessandrini A, Bruzzone B, Icardi G, Garraffo R, De Macina I, Viscoli C, Di Biagio A; HIV/HCV Collaborative Liguria Group.

Int J STD AIDS. 2015 Oct;26(11):831-4. doi: 10.1177/0956462414556330. Epub 2014 Oct 20.

PMID:
25332227
36.

Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates.

Ripamonti D, Tatarelli P, Mangili G, Gotta C, Benatti SV, Bruzzone B, Callegaro A, Viscoli C, Ruggeri M, Di Biagio A.

J Chemother. 2016 Aug;28(4):337-40. doi: 10.1179/1973947814Y.0000000217.

PMID:
25248795
37.

Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G.

World J Gastroenterol. 2014 Aug 7;20(29):9633-52. doi: 10.3748/wjg.v20.i29.9633. Review.

38.

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group.

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.

PMID:
25042976
39.

Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?

Di Biagio A, Prinapori R, Taramasso L, Gustinetti G, Sticchi L, Bruzzone B, Viscoli C.

Recent Pat Antiinfect Drug Discov. 2014;9(1):41-51. Review.

PMID:
25030944
40.

Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo.

Bruzzone B, Bisio F, Caligiuri P, Mboungou FA, Nigro N, Sticchi L, Ventura A, Saladini F, Zazzi M, Icardi G, Viscoli C.

J Virol Methods. 2014 Jul;203:102-6. doi: 10.1016/j.jviromet.2014.02.030. Epub 2014 Mar 30.

PMID:
24694776
41.

Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.

Di Biagio A, Parisini A, Bruzzone B, Prinapori R, Lauriola M, Paolucci S, Signori A, Barresi R, Icardi G, Calderisi S, Meini G, Dentone C, Cenderello G, Guerra M, Maccabruni A, Rusconi S, Viscoli C.

HIV Clin Trials. 2014 Jan-Feb;15(1):45-50. doi: 10.1310/hct1501-45.

PMID:
24518213
42.

Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus.

Sticchi L, Di Biagio A, Rappazzo E, Setti M, De Rosa G, De Hoffer L, Nicolini L, Prinapori R, Bruzzone B.

J Prev Med Hyg. 2013 Jun;54(2):83-6.

43.

Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group.

Svicher V, Alteri C, Montano M, Nori A, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Barresi R, Calderisi S, Callegaro AP, Capobianchi MR, Gargiulo F, Castelli F, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Santo F, Fadda G, Galli M, Gennari W, Ghisetti V, Costantini A, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Nozza S, Paolucci S, Palù G, Parisi S, Parruti G, Pignataro AR, Quirino T, Re MC, Rizzardini G, Sanguinetti M, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Viscoli C, Vullo V, Zazzi M, Lazzarin A, Perno CF.

Infection. 2014 Feb;42(1):61-71. doi: 10.1007/s15010-013-0510-3. Epub 2013 Oct 22.

44.

Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.

Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A.

AIDS Res Hum Retroviruses. 2014 Jan;30(1):17-24. doi: 10.1089/AID.2012.0235. Epub 2013 Sep 17.

45.

Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.

De Hoffer L, Di Biagio A, Bruzzone B, Sticchi L, Prinapori R, Gerbaldo D, Gotta C, Viscoli C.

J Chemother. 2013 Jun;25(3):181-3. doi: 10.1179/1973947812Y.0000000066.

PMID:
23783144
46.

Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).

Rusconi S, Adorni F, Bruzzone B, Di Biagio A, Meini G, Callegaro A, Punzi G, Boeri E, Pecorari M, Monno L, Gianotti N, Butini L, Galli L, Polilli E, Galli M; ARCA Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):E443-6. doi: 10.1111/1469-0691.12229. Epub 2013 Apr 26.

47.

Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo.

Bisio F, Masini G, Blasi Vacca E, Calzi A, Cardinale F, Bruzzone B, Bruzzi P, Viscoli C; Kento-Mwana group.

J Antimicrob Chemother. 2013 Aug;68(8):1862-71. doi: 10.1093/jac/dkt102. Epub 2013 Apr 14.

PMID:
23587655
48.

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.

Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects.

Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21.

49.

Epidemiology of HBV S-gene mutants in the Liguria Region, Italy: Implications for surveillance and detection of new escape variants.

Sticchi L, Caligiuri P, Cacciani R, Alicino C, Bruzzone B.

Hum Vaccin Immunother. 2013 Mar;9(3):568-71. Epub 2013 Jan 7.

50.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4.

Supplemental Content

Loading ...
Support Center